Product Releases

Cancer Biochip for Sequence Capture

Wed, 08/26/2009 - 12:43pm

febit launched a human cancer biochip for HybSelect, febit's automated technology for sequence capture, enabling targeted Next-Generation Sequencing (NGS). The new catalog cancer biochip features 115 important genes which are reported to be associated with common types of cancer by the Wellcome Trust Sanger Institute. The availability of the automated HybSelect technology supports large-cohort NGS studies that aim to elucidate complex diseases such as cancer, drive forward personalized medicine, and investigate new therapeutic delivery models. febit, 877-436-4661,

Share this Story

You may login with either your assigned username or your e-mail address.
The password field is case sensitive.